
    
      Study LP2105521 is a randomized, double-blind, placebo-controlled, parallel-group study to
      examine the safety, tolerability, and effects of rilapladib on plasma Lp-PLA2 activity,
      plaque inflammation, and PAF (if feasible). Subjects will receive placebo or rilapladib once
      daily for 12 weeks. The study will be conducted in subjects with established atherosclerosis.
    
  